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A B S T R A C T   
Objective: To prospectively determine whether diffusion basis spectrum imaging (DBSI) detects, differentiates and 
quantitates coexisting inflammation, demyelination, axonal injury and axon loss in mice with optic neuritis (ON) 
due to experimental autoimmune encephalomyelitis (EAE), and to determine if DBSI accurately measures effects 
of fingolimod on underlying pathology. 
Methods: EAE was induced in 7-week-old C57BL/6 female mice. Visual acuity (VA) was assessed daily to detect 
onset of ON after which daily oral-treatment with either fingolimod (1 mg/kg) or saline was given for ten weeks. 
In vivo DBSI scans of optic nerves were performed at baseline, 2-, 6- and 10-weeks post treatment. DBSI-derived 
metrics including restricted isotropic diffusion tensor fraction (putatively reflecting cellularity), non-restricted 
isotropic diffusion tensor fraction (putatively reflecting vasogenic edema), DBSI-derived axonal volume, axial 
diffusivity, λ‖ (putatively reflecting axonal integrity), and increased radial diffusivity, λ⊥ (putatively reflecting 
demyelination). Mice were killed immediately after the last DBSI scan for immunohistochemical assessment. 
Results: Optic nerves of fingolimod-treated mice exhibited significantly better (p < 0.05) VA than saline-treated 
group at each time point. During ten-week of treatment, DBSI-derived non-restricted and restricted-isotropic- 
diffusion-tensor fractions, and axonal volumes were not significantly different (p > 0.05) from the baseline 
values in fingolimod-treated mice. Transient DBSI-λ‖ decrease and DBSI-λ⊥ increase were detected during Fin-
golimod treatment. DBSI-derived metrics assessed in vivo significantly correlated (p < 0.05) with the corre-
sponding histological markers. 
Conclusion: DBSI was used to assess changes of the underlying optic nerve pathologies in EAE mice with ON, 
exhibiting great potential as a noninvasive outcome measure for monitoring disease progression and therapeutic 
efficacy for MS.   
1. Introduction 
Multiple sclerosis (MS) is an immune-mediated inflammatory 
demyelinating disease of central nervous system (CNS). Irreversible 
axonal injury and axon loss are believed to be major causes of permanent 
neurologic impairments in MS (Rahim et al., 2018; Sun et al., 2020). 
Although early intervention with disease-modifying therapy (DMT) has 
been shown to decrease the relapse rate and slow short-term disability 
progression in MS patients (Montalban et al., 2018), it is still uncertain 
whether it is associated with a lower long-term risk of disability 
(Kavaliunas et al., 2017; Torkildsen et al., 2016). To address this issue, 
robust markers which can precisely capture and discriminate axonal loss 
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from other underlying pathologies, such as inflammation and demye-
lination, and monitor intervention response are urgently needed to help 
clinicians make more efficient personalized management decision for 
MS patients and to assess responses to treatments. 
Optic neuritis (ON) is a frequent manifestation of MS, and is also 
frequently encountered on its own, or as part of other diseases such as 
neuromyelitis optica and myelin oligodendrocyte glycoprotein antibody 
disease. Conventional T2-weighted imaging, T1-weighted gadolinium 
contrast enhanced imaging, magnetization transfer imaging (MTI), and 
diffusion tensor imaging (DTI) have been widely applied on the evalu-
ation of optic nerve in MS-related ON (Hickman et al., 2004, 2005; 
Jackson et al., 1998; Naismith et al., 2012a; Rocca and Filippi, 2007). In 
addition, optic nerve damages in patients with MS have been commonly 
assessed based on optical coherence tomography (OCT) measured 
retinal nerve fiber layer thickness change (Gajamange et al., 2018). 
A lack of pathological specificity of these imaging modalities has 
contributed to discrepancies between neuroimaging findings and clin-
ical outcomes, commonly known as the clinicoradiological paradox 
(Barkhof, 2002; Costello et al., 2006; Davis, 2014), resulting in part from 
the heterogeneous nature of MS in clinical course and underlying pa-
thologies (Leray et al., 2010; Scalfari et al., 2010). We have developed 
diffusion basis spectrum imaging (DBSI) and demonstrated its ability to 
detect and differentiate inflammation, axonal injury, axon loss and 
demyelination in mice with experimental autoimmune encephalomy-
elitis (EAE), and autopsied and biopsied specimens from MS patients 
(Lin et al., 2017; Shirani et al., 2019; Sun et al., 2020; Wang et al., 2014, 
2015, 2011; Ye et al., 2020). 
Therefore, we hypothesized that DBSI, which is pathologically more 
specific than standard MRI, would be able to assess the efficacy of fin-
golimod (also known as FTY720, Selleck Chemicals LLC,) treatment of 
ON through longitudinally quantifying the evolution of several coex-
isting optic nerve pathologies using a preclinical EAE mouse model 
which has ON. 
2. Materials and Methods 
2.1. Animal model 
Procedures were approved by Washington University Institutional 
Animal Care and Use Committee. Female C57BL/6 mice at 7 weeks of 
age were obtained from Jackson Laboratory (Bar Harbor, ME). 
2.2. Induction of EAE and visual acuity (VA) measurements in mice 
Before immunization, 6-week old C57BL/6 mice were housed under 
humidity and temperature-controlled conditions with 12-hour dark/ 
light cycle for two weeks. Mice then underwent baseline DBSI of optic 
nerves, followed acclimation in the facility for another 10–14 days 
before active immunization with myelin oligodendrocyte glycoprotein 
peptide (MOG35-55). Immunization was performed over two sites on the 
flanks with the antigen emulsified in incomplete Freund’s adjuvant 
(IFA), followed by intravenous injections of 200 ng Pertussis toxin (List 
Laboratories, Campbell CA) on days 0 and 2. Sham-EAE was prepared on 
naïve mice with injection of IFA without antigen followed by 200 ng of 
Pertussis toxin on days 0 and 2 (Fig. 1A). 
The VA of mice was measured as previous described using the Virtual 
Optomotry System (Optomotry, Cerebral Mechanics, Inc.). Before im-
munization, normal VA was confirmed for each eye (VA = 0.34 ± 0.04c/ 
d, n = 34 eyes from 17 mice) at baseline. After immunization, blinded 
VA measurement was performed daily before the onset of ON (9–22 days 
post-immunization) which was defined as VA ≤ 0.25c/d in our previous 
study (Chiang et al., 2014; Lin et al., 2017, 2014, 2020), and then 
weekly till the end of the study (Fig. 1B). 
2.3. Fingolimod treatment 
Starting on the first day of onset of ON, mice were alternately 
assigned to either receive daily gavage of fingolimod (n = 9 mice, 1 mg/ 
Fig. 1. Diagram shows experimental design and visual acuity measurement through the entire experiment. (A) DBSI was performed at two weeks prior to active 
immunization (as baseline), 2, 6, and 10 weeks after treatment started. Treatment commenced if one eye visual acuity (VA) ≤ 0.25cycle/degree (c/d). Red-dashed 
line indicates the cut-off VA of 0.25c/d. Daily gavage of either Fingolimod (1 mg/kg) or the equal volume of saline was administrated for 10 weeks. (B) Daily VA was 
performed at the first two weeks after immunization followed by weekly VA from 3 to 10 weeks. Comparing to VA of saline-treated eyes, VA was significant higher in 
Fingolimod-treated eyes from Day 3 to ten-week treatment (p < 0.05). ⋆ indicates p < 0.05, comparing to corresponding saline group. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this article.) 
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kg, Cat No. S5002, Selleck Chemicals LLC) or the same volume of saline 
(n = 9 mice) for 10 consecutive weeks. Mice were alternately assigned to 
receive fingolimod or saline until the 9th pair. The final number in 
fingolimod- and saline-treated group was 8 and 9 EAE mice, respectively 
due to the lack of VA impairment or clinical signs during the course of 
assessment of the last EAE mouse assigned to fingolimod treatment. 
2.4. In vivo diffusion basis spectrum imaging (DBSI) 
In vivo DBSI was performed two weeks before immunization (base-
line DBSI), and then at two, six and ten weeks after initiation of fingo-
limod treatment. DBSI were performed on a 4.7-T small-animal MRI 
scanner (Agilent/Varian) equipped with an Agilent/Magnex HD imag-
ing gradient coil (Magnex/Agilent). Mice were anesthetized with iso-
flurane/O2 [2% (vol/vol) for induction followed by 0.7–0.8% for 
maintenance] throughout the imaging experiment. Body temperature 
was maintained at 37 ◦C with a circulating warm water pad. A diffusion 
weighted mid-sagittal image was acquired to localize mouse optic 
nerves, followed by an oblique image plan perpendicular to the optic 
nerve to obtain the final image view using a multi-echo spin-echo 
diffusion-weighting sequence (Tu et al., 2014). The final diffusion- 
weighted MRI for DBSI analysis employed a 25-direction diffusion- 
encoding scheme adding an extra b = 0 data as previously reported 
(Chiang et al., 2014) with the following acquisition parameters: TR =
1500 ms, TE = 35 ms, NE = 2, inter-echo delay = 20.7 ms, FOV = 22.5 ×
22.5 mm2, matrix size = 192 × 192 (zero-filled to 384 × 384), slice 
thickness = 0.8 mm, maximal b-value = 2,200 s/mm2, total scan time =
2 hr. 4 min. 
2.5. Imaging analysis 
Data was processed with DBSI multi-tensor analysis packages 
developed in-house with Matlab. (Wang et al., 2015, 2011). The imaging 
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⃒ are the signal and b-value of the kth 
diffusion gradient, NAniso is the number of anisotropic tensors (fiber 
tracts), Ψik is the angle between the kth diffusion gradient and the 
principal direction of the ith anisotropic tensor, λ||i and λ⊥i are the axial 
and radial diffusivity of the ith anisotropic tensor, fi is the signal intensity 
fraction for the ith anisotropic tensor, and a and b are the low and high 
diffusivity limits for the isotropic diffusion spectrum (reflecting cellu-
larity and edema) f(D). For a coherent fiber bundle like the optic nerve, 
NAniso = 1. DBSI derived fi represents the density of axons derived from 
retinal ganglion cells (fiber fraction) in the image voxel, taking into 
account of intra-voxel pathological and structural complications. Based 
on prior work, DBSI derived λ|| and λ⊥ reflect axon and myelin integrity 
respectively: ↓ λ|| = axonal injury and ↑ λ⊥ = demyelination. Our pre-
vious experimental findings suggest that the restricted isotropic diffu-
sion fraction reflecting cellularity can be derived by the summation of 
f(D) at 0 ≤ ADC ≤ 0.6 μm2/ms. The summation of the remaining f(D) at 
ADC > 0.6 μm2/ms represents “non-restricted” isotropic diffusion, 
which denotes regions of tissue loss, increased inter-axonal space, 
vasogenic edema and CSF. 
2.6. Regions of interest (ROI) 
ROIs were manually drawn with ImageJ (https://imagej.nih.gov/ij/, 
NIH, US) at the center of each optic nerve on the diffusion-weighted 
image (the edge voxel of optic nerve were avoided), which corre-
sponded to the diffusion gradient direction perpendicular to optic 
nerves, to minimize partial volume effects. ROIs were then transferred to 
the parametric maps to calculate the mean value for individual DBSI 
metrics. A separate ROI encompassing the whole optic nerve was drawn 
on cross-sectional images obtained with diffusion weighting gradient 
direction orthogonal to optic nerve (larger than the ROIs for other DBSI 
metrics). The ROI included the edge voxel of optic nerve. DBSI-derived 
fiber volume was calculated from the optic nerve volume (the entire ROI 
on DWI) multiplied by the corresponding DBSI fiber fraction. The dilu-
tion effect of inflammation and surrounding CSF is considered in the 
fiber volume computation in the manner (Lin et al., 2020). 
2.7. Histology analysis 
After the last DBSI scan, mice were killed and the optic nerves were 
collected and embedded in 2% agar gel (Blewitt et al., 1982), followed 
by paraffin embedding of the agar block. The paraffin blocks were cut in 
the axial plane at a thickness of 5-µm for immunohistochemistry (IHC) 
staining, including SMI-31, SMI-312, MBP, and DAPI. The whole field of 
SMI-31, MBP, and DAPI stained images at 100 × magnification with oil 
lens was captured with the same fluorescence light intensity and expo-
sure time for each image. All captured images were converted to 8-bit 
gray scale and analyzed using threshold, edge enhancement, analyze 
particles and gray level watershed segmentation functions in ImageJ 
(https://imagej.nih.gov/ij/, NIH, US). Nucleus counts were performed 
by signal intensity threshold on DAPI staining (Lin et al., 2017, 2020). 
2.8. Statistical analysis 
Data were presented as mean ± standard deviation. VA and MRI 
measurements were performed on each eye at baseline, end of two-, six- 
and ten-week treatment. Data were analyzed with a mixed random ef-
fects repeated measures model with side, time, treatment, and time by 
treatment interaction as fixed effects. Mouse within treatment was a 
random effect. Correlation of repeated-measures was estimated in a first- 
order auto-regressive covariance structure. Variance components were 
estimated by group to account for differences in variance. Regression of 
MRI measurements on histology measures were performed with mixed 
random effect regression to account for two eyes measured for each 
mouse. 
3. Results 
3.1. Visual acuity (VA) in fingolimod-treated mice was better than that in 
saline-treated mice 
There was no VA difference between fingolimod-treated (0.34 ±
0.03c/d, n = 16 eyes, from 8 EAE mice) and saline-treated groups (0.36 
± 0.04c/d, n = 18 eyes, from 9 EAE mice) at baseline before treatment. 
Over the treatment period, the VA of fingolimod-treated mice was 
significantly better than saline-treated mice from 3 days to 10 weeks 
after treatment onset (p < 0.05, Fig. 1B). 
3.2. DBSI detected the reduced inflammation in fingolimod-treated optic 
nerves 
Representative DBSI non-restricted isotropic fraction (putatively 
reflecting vasogenic edema) and restricted isotropic fraction (putatively 
reflecting cellularity) maps of optic nerves were presented to demon-
strate the evolution of these markers at baseline (before immunization), 
2, 6, and 10 weeks after treatment (Fig. 2A). 
In the group of saline-treated mice with ON, non-restricted isotropic 
fraction of optic nerves significantly increased from baseline by 133% (p 
= 0.020), 198% (p = 0.001), and 229% (p < 0.001) at 2, 6, and 10 weeks 
after treatment, respectively (Fig. 2B). Restricted isotropic fraction of 
optic nerves significantly increased from the baseline by 201% (p <
0.001), 98% (p = 0.070), and 164% (p = 0.002) at 2, 6, and 10 weeks 
after placebo treatment, respectively (Fig. 2C). In the fingolimod 
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treatment group, non-restricted isotropic fraction increased from base-
line by 21% (p = 0.740), 48% (p = 0.440), and 63% (p = 0.320) at 2, 6, 
and 10 weeks after treatment (Fig. 2B), while restricted isotropic frac-
tion increased from baseline by 72% (p = 0.180), 28% (p = 0.590), and 
51% (p = 0.340) at 2, 6, and 10 weeks (Fig. 2C). 
In comparison to the saline-treated group, the fingolimod-treated 
mice exhibited significantly lower non-restricted isotropic fraction at 2 
(60% lower, p = 0.070), 6 (62% lower, p = 0.020) and 10 weeks (63% 
lower, p = 0.010) after treatment (Fig. 2B). Although the increase in 
restricted isotropic fraction was numerically greater for the placebo 
group, differences between the two treatment groups were not statisti-
cally significant. 
3.3. DBSI detected reduced axon loss in fingolimod-treated optic nerves 
Representative fiber fraction (the total diffusion signal from aniso-
tropic axonal fiber bundles) maps of optic nerves at baseline, 2, 6, and 
10 weeks after treatment were presented to demonstrate the evolution of 
fiber fraction (Fig. 3A). 
In the saline-treated group, DBSI fiber fraction (putative marker of 
apparent axonal density) of the optic nerves decreased by 10% (p =
0.140), 24% (p = 0.002) and 25% (p = 0.003) at 2, 6, and 10 weeks, 
respectively, when compared to baseline before immunization (Fig. 3B). 
DWI-derived volumes of optic nerves decreased by 23% (p = 0.004), 
37% (p < 0.001) and 25% (p = 0.002) at 2, 6, and 10 weeks, respec-
tively, from baseline before immunization (Fig. 3C). DBSI-derived 
axonal volume (putative marker of axonal content) decreased by 28% 
Fig. 2. DBSI-derived non-restricted fraction 
(putative edema) and restricted (putative 
cellularity) isotropic tensor fraction maps for 
representative saline- and fingolimod-treated 
optic nerves from baseline to 10-week treat-
ment (A). Comparing to baseline, fingolimod 
effectively suppressed putative inflammation 
markers, including non-restricted and 
restricted fractions, after treatment (p <
0.05, B and C). However, significant increase 
in saline-treated optic nerves from baseline 
was shown in non-restricted fraction at all 
time points (p < 0.05) and in restricted 
fraction at 2 and 10 (both p < 0.05) but not 
at 6 (p = 0.06) weeks (B and C). Comparing 
to saline, significantly reduced non-restricted 
fraction at 6 and 10 weeks (p < 0.05) in 
fingolimod-treated optic nerves (B). Mild but 
not significant reduced restricted fraction 
was shown in fingolimod-treated optic nerve 
all the time (C). ⋆ indicates p < 0.05, 
comparing between saline and fingolimod 
groups $ indicates p < 0.05, comparing to its 
baseline within group.   
Fig. 3. DBSI-derived fiber fraction reflects 
total signal from anisotropic diffusion tensor 
components, reflecting axonal fiber density 
(A, B). Comparing to baseline, significantly 
decreased fiber fraction was detected at each 
time point in saline-treated group (p < 0.05) 
but not in fingolimod-treated optic nerves at 
all time points (B). Significantly reduced 
DWI-derived nerve volume was seen in 
saline-treated optic nerves (p < 0.05) but not 
in fingolimod-treated group from baseline to 
the rest of time points (C). To remove the 
confounding effects from inflammation, 
DBSI-derived axonal volume (D) was 
computed multiplying fiber fraction (B) by 
DWI-derived nerve volume (C) in each indi-
vidual optic nerve. Comparing to baseline, 
significantly reduced DBSI-derived axonal 
volume was shown in saline-treated optic 
nerves (p < 0.05) but not in fingolimod- 
treated optic nerves at all time points (D). 
Comparing to saline group, fingolimod- 
treated optic nerves showed significantly 
higher axon volume at all time points (D), 
suggesting axonal prevention with fingoli-
mod treatment. ⋆ indicates p < 0.05, 
comparing between saline and fingolimod 
groups $ indicates p < 0.05, comparing to its baseline within group.   
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(p = 0.006), 45% (p < 0.001), and 36% (p < 0.001) at 2, 6, and 10 
weeks, respectively, when compared to baseline before immunization 
(Fig. 3D). In the fingolimod-treated group, no significant difference from 
baseline was observed for DBSI fiber fraction, DWI-derived optic nerve 
volume, or DBSI axonal volume at any time point after treatment. 
Compared to saline-treated mice, the fingolimod-treated group 
exhibited significantly higher DBSI fiber fraction at 6 weeks (38% 
higher, p = 0.020) and 10 weeks (Fig. 3B, 33% higher, p = 0.030), with 
significantly lower DWI-derived optic nerve volumes at 6 weeks (35% 
higher, p = 0.02) and at 10 weeks (39% higher, p = 0.005, Fig. 3C). 
DBSI-derived axonal volumes in the fingolimod-treated optic nerves 
were higher than for saline-treated optic nerves at 2 weeks (25% higher, 
p = 0.400), 6 weeks (62% higher, p = 0.020) and 10 weeks (64% higher, 
p = 0.007) after treatment commencement (Fig. 3D). 
3.4. DBSI detection of diminished injury to residual axons in fingolimod- 
treated optic nerves 
Fig. 4A shows representative DBSI axial diffusivity (λ‖) and radial 
diffusivity (λ⊥) maps at baseline, 2, 6, and 10 weeks after treatment for 
each group. Compared to baseline, for saline-treated mice DBSI λ‖
significantly decreased by 17% (p < 0.001), 14% (p < 0.001), and 12% 
(p = 0.001) at 2, 6, and 10 weeks (Fig. 4B), while DBSI λ⊥ significantly 
increased by 45% (p = 0.015), 62% (p = 0.001) and 75% (p < 0.001) at 
2, 6, and 10 weeks (Fig. 4C), respectively. In the fingolimod treatment 
group, DBSI λ‖ decreased by 7% (p = 0.040), 7% (p = 0.033), 3% (p =
0.330) at 2, 6, 10 weeks (Fig. 4B), while DBSI λ⊥ increased from baseline 
by 14% (p = 0.400), 15% (p = 0.400) and 9% (p = 0.600) at 2, 6 and 10 
weeks after treatment (Fig. 4C). 
Compared the difference between groups (saline vs. fingolimod), 
fingolimod-treated group showed no significant differences on DBSI λ‖
for all the time points while DBSI λ⊥ decreased by 38% at 10 weeks (p =
0.010, Fig. 4C). 
3.5. Immunohistochemistry (IHC) staining of optic nerves 
Mice were euthanized at the end of the treatment period for histo-
logic assessment of the optic nerves. IHC staining of total neurofilaments 
(SMI-312, stains both injured and intact axons), phosphorylated neu-
rofilaments (SMI-31, stains intact axons), and myelin basic protein 
(MBP, stains myelin) revealed that the saline-treated group exhibited 
less staining for SMI-312 (Fig. 5A), MBP (Fig. 5D), and SMI-31 (Fig. 5G), 
when compared to fingolimod-treated group (Fig. 5B, E, H). The 
apparent optic nerve sizes of saline-treated group were smaller than 
those of fingolimod-treated group (Fig. 5A–I). However, compared to 
one representative wildtype (WT) optic nerves (10-week-old C57BL/6 
female mouse optic nerve), fingolimod-treated group showed enlarged 
staining spots (Fig. 5b, e, h; blue arrows), suggesting swollen axons or 
myelin debris aggregation. Moreover, increased positive DAPI staining 
areas (cell nuclei) were also seen in both saline and fingolimod treat-
ment groups compared to WT optic nerve, suggesting increased cellu-
larity (Fig. 5J and K). 
DBSI λ‖, DBSI λ⊥, DBSI-derived axon volume, and DBSI restricted/ 
non-restricted fractions correlated well with SMI-31 area fraction 
(Fig. 6A), MBP area fraction (Fig. 6B), SMI-312 area fraction (Fig. 6C) 
and DAPI density (Fig. 6D/E), respectively in the ON-affected optic 
nerves. 
4. Discussion 
Understanding of the evolution of chronic human CNS diseases over 
time and response to therapies has been hindered by inability to access 
CNS specimens to examine longitudinally. In this study, we hypothe-
sized that DBSI is capable to assess the efficacy of fingolimod treatment 
in an animal model of ON. The optic nerve was chosen for examination 
because it is a frequent site of inflammatory demyelination in MS and 
related diseases. Moreover, the volume of the optic nerve can be 
measured, allowing precise measurement of axonal content, even in the 
presence of inflammation and edema. Previously, DTI has played a 
significant role to noninvasively identify axonal injury and demyeli-
naiton in MS subjects (Kuchling et al., 2017; Naismith et al., 2009, 
2012b; Smith et al., 2011) or its animal models (Sun et al., 2007). 
However, single-tensor DTI-determined axonal injury or demyelination 
may be confounded by coexisting inflammation limiting its ability to 
accurately assess the severity of axonal loss, a hallmark pathology of 
disease progression. DBSI is a data-driven approach modeling diffusion- 
weighted MRI signals as a linear combination of multiple anisotropic 
and isotropic tensors to resolve the underlying structural and patho-
logical complexity. Thus, DBSI noninvasively quantifies coexisting pa-
thologies over time and quantitatively assesses axonal loss in fingolimod 
(an FDA-approved oral medication for MS) or saline-treated optic 
nerves. 
Optic neuritis, a common occurrence in people with MS, can lead to 
irreversible visual impairment (Galetta et al., 2015). Fingolimod is 
approved for patients with RRMS. However, its neuroprotective effects 
remain uncertain (Ambrosius et al., 2017). Rau et al. reported apoptotic 
Fig. 4. DBSI-derived axial (λ‖) and radial 
(λ⊥) diffusivity maps of representative saline- 
and fingolimod-treated optic nerves from 
baseline to 10-week treatment (A) were 
derived from anisotropic diffusion tensor 
components. Comparing to baseline, signifi-
cantly decreased DBSI-λ‖ was detected at all 
time points in saline-treated optic nerves (B, 
p < 0.05). In contrast, decreased DBSI- λ‖
was only seen at 2 and 6 weeks in 
fingolimod-treated optic nerves (B, p <
0.05). Significantly increased DBSI-λ⊥ was 
detected in saline-treated (p < 0.05) but not 
in fingolimod-treated optic nerves at all time 
points (C). The results showed intermittent 
axonal injury during fingolimod treatment. 
After 10-week fingolimod treatment, DBSI-λ‖
and DBSI-λ⊥ were not different from their 
baseline values (B, C). ⋆ indicates p < 0.05, 
comparing between saline and fingolimod 
groups $ indicates p < 0.05, comparing to its 
baseline within group.   
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cell death of retinal ganglion cells in rats with EAE that were treated 
with fingolimod, although axonal preservation in optic nerves was seen 
by histological data (Rau et al., 2011). An et al. reported axonal pres-
ervation in optic nerves by histological validation and moderate visual 
dysfunction (better than non-treated EAE mice but worse than naïve 
control mice) by optometry (An et al., 2013). However, both studies 
could only rely upon end-point histological results at the conclusion of 
study to evaluate whether fingolimod is axonal protective. In the current 
study, DBSI detected improved transient inflammation (via the putative 
inflammatory markers: restricted fraction → inflammatory cellularity 
Fig. 5. Representative 100 × immunohisto-
chemical staining images of total neurofila-
ment (SMI-312, staining both injured and 
intact axons, A–C), myelin basic protein 
(MBP, assessing myelin, D–E), phosphory-
lated neurofilament (SMI-31, reflecting 
intact axons, G–I), and 4′, 6-dianidino-2-phe-
nylindole (DAPI, detecting nuclei, J – L) from 
saline-, and fingolimod-treated optic nerves 
at 10 weeks after treatment. Comparing to 
wild-type (WT) optic nerves, saline-treated 
optic nerves showed lowest staining in-
tensity in SMI-312 (A), MBP (D), and SMI-31 
(G), suggesting axonal loss, demyelination, 
and axonal injury, respectively. In contrst, 
moderate lower staining intensity in SMI-312 
(B), MBP (E), and SMI-31(H), suggesting 
mild axon and myelin injury were assessed in 
fingolimod-treated optic nerves. Blue arrows 
indicated swelling axon and myelin. Stron-
gest DAPI stains in saline-treated optic nerve 
(J) suggested highest cellularity than 
fingolimod-treated (K) and wild-type (L) optic nerves.White scale bar: 50 μm Yellow scale bar: 10 μm. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.)   
Fig. 6. Mixed random-effect regression 
analysis for the correlation between DBSI 
parameters and IHC biomarkers. SMI-31 
counts and MBP area fraction (the ratio of 
positive staining counts and total tissue 
area), SMI-312 area (absolute value of posi-
tive staining counts), and DAPI counts were 
statistically significant associated with DBSI- 
λ‖ (A), DBSI-λ⊥ (B), DBSI-derived axonal 
volume (C), DBSI restricted isotropic fraction 
(D), and DBSI non-restricted isotropic frac-
tion (E), suggesting that in vivo DBSI quan-
titatively reflected the complicated 
pathologies including axonal injury, demye-
lination, axonal loss, and cell infiltration.   
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and non-restricted fraction → vasogenic edema) and axonal pathologies 
(via putative DBSI axonal injury and loss markers) in fingolimod-treated 
optic nerves. Results suggest axonal protection of fingolimod could be 
secondary to reduced inflammation. 
We observed that daily oral fingolimod markedly reduced inflam-
mation, evidenced by the decrease in DBSI restricted isotropic fraction 
(reflecting cellular inflammation) and non-restricted isotropic fraction 
(reflecting vasogenic edema), in accordance with the action of fingoli-
mod to sequester lymphocytes in secondary lymphoid tissue and thus 
inhibit lymphocytes from entering the CNS (Zhang et al., 2015b). 
Additionally, we also observed that both decreased λ|| (putative axonal 
injury, Fig. 4B) and increased λ⊥ (putative demyelination, Fig. 4C) were 
significantly improved in mice treated with fingolimod versus those 
treated with saline. Mice were euthanized and optic nerves were 
examined histologically at the conclusion of 10-week treatment. As 
previously reported (Lin et al., 2017, 2020) DBSI longitudinally moni-
tored disease progression. After 10 weeks of fingolimod therapy, 
reduced inflammation, less demyelination, and diminished axonal 
injury of optic nerves was confirmed by IHC, suggesting DBSI is capable 
of detecting long-term anti-inflammatory and neuroprotective effects 
with fingolimod treatment. The histological findings were consistent 
with DBSI-derived putative imaging biomarkers of optic nerve pathol-
ogies. Following increased λ⊥ (demyelination) in optic nerves of EAE 
mice with ON, we noted the subsequent reduction of DBSI λ⊥ after 10 
weeks of fingolimod but not placebo treatment, suggesting remyelina-
tion could have occurred in those mice treated with fingolimod. There is 
no direct histological data to validate in this study, but the profile of 
DBSI-derived λ⊥ was consistent with other reports (Yazdi et al., 2020; 
Zhang et al., 2015a). 
Limitations of the current study include that we performed histo-
logical validation at the last time point, 10 weeks after treatment 
commenced. Definitive demonstration of the evolution of the underlying 
optic nerve pathologies may require further cross-sectional histological 
validation studies. Second, this proof-of-concept study may be limited 
due to the small sample size (17 mice divided between fingolimod and 
saline treatment groups). Although each mouse was imaged 4 times, 
generating 68 imaging datasets thus increasing the power of the study, 
the limitation of small number of animals studied needs to be kept in 
mind when drawing a conclusion. Third, visual function is not specific to 
optic nerve pathologies since EAE (and MS) can affect other parts of the 
visual system, such as retinal ganglion cells (Shindler et al., 2006). 
Damage in regions other than the optic nerves was not taken into 
consideration in the present study. Finally, not all DBSI pathologic 
metrics have corresponding IHC markers. For example, non-restricted 
fraction is a putative marker of vasogenic edema in vivo, associated 
with inflammation in EAE. However, postmortem histology is not suit-
able for validating this metric due to fixation and paraffin embedding for 
IHC analysis although indirect evidence does support that non-restricted 
fraction is associated with inflammation (Fig. 6E, correlation between 
non-restricted fraction and DAPI). 
In conclusion, our preclinical study demonstrates that DBSI-based 
biomarkers reflect underlying pathologic changes and, importantly, 
therapeutic efficacy of an established treatment. Moreover, the results 
strongly suggest that DBSI can detect and quantitate remyelination 
following demyelination. These data support that DBSI, a noninvasive 
contrast agent-free MR technique, offers new possibilities for precise 
clinical diagnosis as well as assessing disease evolution and treatment 
responses in CNS inflammatory demyelinating diseases, such as MS. 
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